Current Hypertension Reports

, Volume 10, Issue 1, pp 32–38 | Cite as

Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight into global cardiometabolic risk

Article

Abstract

Increasing evidence supports the role of adipose tissue in the development of a systemic inflammatory state, which contributes to obesity-associated vasculopathy and cardiovascular risk. In addition to storing calories as triglycerides, adipocytes secrete a large variety of proteins, including cytokines, chemokines, and hormone-like factors (eg, leptin, adiponectin, resistin). This production of pro chemokines by adipose tissue is of particular interest, because their local secretion by perivascular adipose depots may provide a new mechanistic link between obesity and its associated vascular complications. Insulin resistance, in subjects with or without diabetes, is frequently associated with obesity, particularly with an excess of intra-abdominal fat. Recently, the endocannabinoid system, among others, has been shown to be involved in the pathophysiology of visceral obesity and global cardiometabolic risk, as represented by the overall risk of developing type 2 diabetes or cardiovascular diseases.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.PubMedCrossRefGoogle Scholar
  2. 2.
    Peelman F, Waelput W, Iserentant H, et al.: Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res 2004, 43:283–301.PubMedCrossRefGoogle Scholar
  3. 3.
    Yudkin JS, Kumari M, Humphries SE: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148:209–214.PubMedCrossRefGoogle Scholar
  4. 4.
    Rennie KL, Jebb SA: Prevalence of obesity in Great Britain. Obes Rev 2005, 6:11–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Engstrom G, Stavenow L, Hedblad B, et al.: Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 2003, 52:442–447.PubMedCrossRefGoogle Scholar
  6. 6.
    Calabro P, Yeh ET: Inflammatory vascular markers in atherosclerosis. In Current Topics in Atherosclerosis Research. Edited by Geng YJ. Hauppauge: Nova Science Publishers; 2005:49–65.Google Scholar
  7. 7.
    Yudkin JS: Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S25–S28.PubMedCrossRefGoogle Scholar
  8. 8.
    Calabro P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108:1930–1932.PubMedCrossRefGoogle Scholar
  9. 9.
    Calabro P, Chang DW, Willerson JT, Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112–1113.PubMedCrossRefGoogle Scholar
  10. 10.
    Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.PubMedCrossRefGoogle Scholar
  11. 11.
    Calabro P, Chang DW, Willerson JT, Yeh ET: Production of C-reactive protein and serum amyloid A in response to inflammatory cytokines by human adipocytes. Eur H Journal 2005, 26(Suppl):334–335.Google Scholar
  12. 12.
    Ouchi N, Kihara S, Arita Y, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296–1301.PubMedGoogle Scholar
  13. 13.
    Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327–332.PubMedCrossRefGoogle Scholar
  14. 14.
    Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972–978.PubMedGoogle Scholar
  15. 15.
    Itoh K, Imai K, Masuda T, et al.: Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 2002, 25:881–886.PubMedCrossRefGoogle Scholar
  16. 16.
    De Pergola G, Pannacciulli N: Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002, 25:899–904.PubMedGoogle Scholar
  17. 17.
    Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003, 100:7265–7270.PubMedCrossRefGoogle Scholar
  18. 18.
    Weyer C, Yudkin JS, Stehouwer CD, et al.: Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002, 161:233–242.PubMedCrossRefGoogle Scholar
  19. 19.
    Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.PubMedCrossRefGoogle Scholar
  20. 20.
    Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745–E751.PubMedGoogle Scholar
  21. 21.
    Mohamed-Ali V, Goodrick S, Rawesh A, et al.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196–4200.PubMedCrossRefGoogle Scholar
  22. 22.
    Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327–334.PubMedCrossRefGoogle Scholar
  23. 23.
    Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767–72.PubMedGoogle Scholar
  24. 24.
    Halaas JL, Gajiwala KS, Maffei M, et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543–546.PubMedCrossRefGoogle Scholar
  25. 25.
    Oral EA, Simha V, Ruiz E, et al.: Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570–578.PubMedCrossRefGoogle Scholar
  26. 26.
    Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307–312.PubMedCrossRefGoogle Scholar
  27. 27.
    Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al.: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452–5455.PubMedCrossRefGoogle Scholar
  28. 28.
    Patel L, Buckels AC, Kinghorn IJ, et al.: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472–476.PubMedCrossRefGoogle Scholar
  29. 29.
    Verma S, Li SH, Wang CH, et al.: Resistin promotes endothelial cell activation: further evidence of adipokineendothelial interaction. Circulation 2003, 108:736–740. [Published erratum appears in Circulation 2004, 109:2254.]PubMedCrossRefGoogle Scholar
  30. 30.
    Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004, 110:3335–3340.PubMedCrossRefGoogle Scholar
  31. 31.
    Burnett MS, Lee CW, Kinnaird TD, et al.: The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182:241–248.PubMedCrossRefGoogle Scholar
  32. 32.
    Lee JH, Bullen JW Jr, Stoyneva VL, Mantzoros CS: Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia. Am J Physiol Endocrinol Metab 2005, 288:E625–E632.PubMedCrossRefGoogle Scholar
  33. 33.
    Vendrell J, Broch M, Vilarrasa N, et al.: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004, 12:962–971.PubMedCrossRefGoogle Scholar
  34. 34.
    Fruebis J, Tsao TS, Javorschi S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005–2010.PubMedCrossRefGoogle Scholar
  35. 35.
    Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.PubMedCrossRefGoogle Scholar
  36. 36.
    Hotta K, Funahashi T, Bodkin NL, et al.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126–1133.PubMedCrossRefGoogle Scholar
  37. 37.
    Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.PubMedGoogle Scholar
  38. 38.
    Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057–1063.PubMedGoogle Scholar
  39. 39.
    Kumada M, Kihara S, Ouchi N, et al.: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046–2049.PubMedCrossRefGoogle Scholar
  40. 40.
    Chen H, Montagnani M, Funahashi T, et al.: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021–45026.PubMedCrossRefGoogle Scholar
  41. 41.
    Kawanami D, Maemura K, Takeda N, et al.: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004, 314:415–419.PubMedCrossRefGoogle Scholar
  42. 42.
    Ouchi N, Kobayashi H, Kihara S, et al.: Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004, 279:1304–1309.PubMedCrossRefGoogle Scholar
  43. 43.
    Boden G, Zhange M: Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006, 15:243–250.PubMedCrossRefGoogle Scholar
  44. 44.
    Brekke HK, Lenner RA, Taskinen MR, et al.: Lifestyle modification improves risk factors in type 2 diabetes relatives. Diabetes Res Clin Pract 2005, 68:18–28.PubMedCrossRefGoogle Scholar
  45. 45.
    Koh KK, Quon MJ, Han SH, et al.: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687–3692.PubMedCrossRefGoogle Scholar
  46. 46.
    Koh KK, Han SH, Quon MJ: Beneficial effects of feno-fibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419–1424.PubMedCrossRefGoogle Scholar
  47. 47.
    Ridker PM, Koenig W, Fuster V: C-reactive protein and coronary heart disease. N Engl J Med 2004, 351:295–298; author reply 295–298.PubMedCrossRefGoogle Scholar
  48. 48.
    Calabro P, Willerson JT, Yeh ET. Inflammation, C-reactive protein, and vulnerable plaque. In Cardiovascular Medicine. Edited by Willerson JT, Cohn JN, Wellens HJJ, Holmes DR. New York: Springer; 2007:611–618.CrossRefGoogle Scholar
  49. 49.
    Esposito K, Pontillo A, Di Palo C, et al.: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799–1804.PubMedCrossRefGoogle Scholar
  50. 50.
    Esposito K, Marfella R, Ciotola M, et al.: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292:1440–1446.PubMedCrossRefGoogle Scholar
  51. 51.
    Okita K, Nishijima H, Murakami T, et al.: Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004, 24:1868–1873.PubMedCrossRefGoogle Scholar
  52. 52.
    Ouchi N, Kihara S, Funahashi T, et al.: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671–674.PubMedCrossRefGoogle Scholar
  53. 53.
    Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.PubMedCrossRefGoogle Scholar
  54. 54.
    Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347–355.PubMedCrossRefGoogle Scholar
  55. 55.
    Calabro P, Samudio I, Safe SH, et al.: Inhibition of tumornecrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. J Vasc Res 2005, 42:509–516.PubMedCrossRefGoogle Scholar
  56. 56.
    Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679–684.PubMedCrossRefGoogle Scholar
  57. 57.
    Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al.: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169–2176.PubMedCrossRefGoogle Scholar
  58. 58.
    Pagotto U, Pasquali R: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005, 365:1363–1364.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Division of Cardiology, Department of Cardiothoracic SciencesSecond University of NaplesNaplesItaly

Personalised recommendations